A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
NCT04867616
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
466
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer's Disease
Interventions
OTHER:
Placebo
BIOLOGICAL:
Bepranemab
Sponsor
UCB Biopharma SRL